Join us Tuesday, November 17, at 10 AM – 11 AM ET for an update on CARB-X, and an insider’s look at 3 innovative programs supported by CARB-X

CARB-X is hosting this special webinar to showcase some of the exciting science in the CARB-X portfolio and the progress CARB-X is making supporting the development of innovative therapeutics, preventatives and rapid diagnostics to address antibiotic-resistant bacteria.

The webinar will be moderated by Kevin Outterson, Executive Director of CARB-X, and will feature

• Erin Duffy, CARB-X R&D Chief, on portfolio priorities and progress
• Xavier Duportet, Co-Founder and CEO of Eligo Bioscience, on Eligo’s innovative CRISPR-based therapeutics derived from bacteriophages to prevent and treat antibiotic-resistant infections in transplant patients
• Jonathan Steckbeck, Founder and CEO of Peptilogics, on the development of their first-in-class antibiotic peptide for the treatment of prosthetic joint infections which recently was granted Orphan Drug Designation by the US Food and Drug Administration
• Bernat Olle, Co-Founder and CEO of Vedanta Biosciences, on Vedanta’s microbiome program, including VE707, an oral therapeutic designed to restore a patient’s healthy microbiota to that it can fight multidrug-resistant bacteria, and VE303, which has recently become the first CARB-X-funded therapeutic to go on to secure BARDA support for late-stage development, and is also the first-ever BARDA award for research and development of a live bio-therapeutic product.

A virtual Q&A will also be held.

CLICK HERE TO REGISTER TODAY:
Once you register, you will receive a confirmation and will be able to download an invitation to your calendar.